
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Pivotal has announced that it will provide specialized clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma in the treatment of hospitalized patients with COVID-19. The two-phase study is a multicenter, randomized, sequential and adaptive design clinical trial that will use the plasma extracted from about 200 convalescent patients with COVID-19 to treat patients in the acute phase of this disease, compared with standard treatment.
For more information on the study, click






